Press Release Headlines

Shortages of Potassium Iodide as Radiation Panic Drives Demand

Physician Says New BioShield Pill Offering Superior Radiation Protection Is Available Now

DENVER, March 28, 2011 — The Japanese nuclear crisis has caused a surge in the demand of potassium iodide, causing shortages not only in Japan, but as far away as California, western Canada, and even southeastern Russia. Although potassium iodide does not provide generalized radiation protection because it only shields the thyroid, manufacturers and pharmacies are being bombarded with orders as the radiation hysteria mounts.

A new and superior product, known as the BioShield Radiation Pill, could restore calm to worried residents in affected areas. Scientists at Premier Micronutrient Corporation have developed this pill as the first ever that is proven to protect DNA from damage caused by radiation. The product was originally developed at the request of the Marine Corps after 9/11 to protect military personnel from the adverse effects of radiation they might encounter while fighting in the Middle East. Research conducted with the Department of Defense, NASA, and prominent universities has demonstrated effectiveness in addressing radiation-induced oxidative stress.

Dr. James Ehrlich was on the team that developed this groundbreaking pill. Invite this engaging and knowledgeable guest to answer:

  • Should all residents near nuclear plants have the BioShield pill in case of a radiation emergency?
  • Is this pill safe for young children?
  • How does the BioShield pill work differently from potassium iodide?
  • How long after exposure can this pill provide protective benefits?
  • Is this pill available without a prescription?

CREDENTIALS: Dr. James Ehrlich is a Clinical Associate Professor at the University of Colorado and an Adjunct Assistant Professor in the department of medicine at the George Washington University Medical Center. He is the medical director of Early Detection Technologies, LLC, which advises on best practices involving biomarkers, imaging technologies, and radiation protection. Involved in atherosclerosis research at two medical schools, Dr. Ehrlich is a founding member of the Society of Atherosclerosis Imaging, a co-founder of the Society of Cardiovascular CT, and he created the Society for Responsible Preventive Imaging. He is head of the medical advisory board of U.S. Preventive Medicine and is on the board of Premier Micronutrient Corporation with a particular focus on biologic radiation protection. Dr. Ehrlich is a co-author of a multimedia CD called The Physician's Guide to Coronary Imaging. He has appeared on over 200 TV and radio programs nationwide.

CONTACT: James Ehrlich, M.D., (303) 808-6470 (CO); Email;
http://www.bioshieldpill.com and http://www.premiermicronutrient.com

# # #